期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

II期结肠癌术后辅助化疗进展 被引量：6

原文传递
导出
摘要 结肠癌是最常见的恶性肿瘤之一。Ⅲ期结肠癌根治术后采用含氟尿嘧啶（5一FU）的辅助化疗已经成为标准的治疗．而Ⅱ期结肠癌患者术后是否进行辅助化疗、如何选用合适的化疗尚存在争议。因为多项研究发现．Ⅱ期结肠癌患者从术后辅助化疔中获益的比例仅为2％～5％。如何甄别出能够从辅助化疗中真正获益的患者．并且提供合适的化疗．是临床的焦点问题。
作者 吕敏 鲁智豪 沈琳
机构地区 北京大学临床肿瘤学院北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室北京肿瘤医院消化肿瘤内科
出处 《中华胃肠外科杂志》 CAS 北大核心 2011年第8期653-656,共4页 Chinese Journal of Gastrointestinal Surgery
关键词 术后辅助化疗 结肠癌 癌患者 恶性肿瘤 氟尿嘧啶 根治术后 焦点问题 Ⅱ期
分类号 R735.35 [医药卫生—肿瘤]
  • 相关文献

参考文献38

  • 1Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol, 2004,22(16):3395- 3407.
  • 2Quasar Collaborative Group, Gray R, Bamwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 2007,370 (9604) : 2020-2029.
  • 3Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009,27(19) :3109-3116.
  • 4Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol, 2009,27(6):872-877.
  • 5Rosenberg R, Maak M, Nitsche U, et al. Independent validation of a prognostic genomic profile (ColonPrint) for stage II colon cancer (CC) patients. 2010 ASCO meeting. J Clin Oncol, 2010,18:abstr 3513.
  • 6Wilson PM, Ladner RD, Lenz HJ. Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res, 2007,1 (6) : 237-246.
  • 7Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med, 2003,349 (3) : 247-257.
  • 8Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage Ⅱ and Ⅲ colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol, 2008,26 : abstr 4008.
  • 9Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol, 2011,29(10) : 1261-1270.
  • 10Sinicrope F, Foster NR, Sargent DJ, et al. DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. J Clin Oncol, 2010,28 : ahstr 3519.

同被引文献45

引证文献6

二级引证文献27

中华胃肠外科杂志
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部